Abiopharma

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Anavex Joins ACCESS-AD, Major Initiative Funded by the EU Commission, through Clinical Evaluation of Blarcamesine as Part of Precision Medicine in AD

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

(90% Positive) Armata Pharmaceuticals Inc. (ARMP) Announces Enrollment Update for initiate Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(30% Negative) Sono-Tek Corp (SOTK) Reports Q1 2026 Financial Results

(70% Positive) Sight Sciences Inc (SGHT) Reports Q1 2026 Financial Results

(90% Positive) Kymera Therapeutics Inc (KYMR) Announces Enrollment Update for medicines Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(90% Positive) uniQure NV (QURE) Announces Enrollment Update for option Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

(90% Positive) Energous Co (WATT) Reports Q1 2026 Financial Results

(99% Neutral) Bausch Health Companies Inc (BHC) Reports Q1 2026 Financial Results

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines